WO2011019634A3 - Aryl substituted sulfonamide compounds and their use as anticancer agents - Google Patents
Aryl substituted sulfonamide compounds and their use as anticancer agents Download PDFInfo
- Publication number
- WO2011019634A3 WO2011019634A3 PCT/US2010/044839 US2010044839W WO2011019634A3 WO 2011019634 A3 WO2011019634 A3 WO 2011019634A3 US 2010044839 W US2010044839 W US 2010044839W WO 2011019634 A3 WO2011019634 A3 WO 2011019634A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aryl substituted
- anticancer agents
- substituted sulfonamide
- sulfonamide compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Abstract
Aryl substituted sulfonamide compounds of formula (I) are disclosed. Also disclosed is a method for treating cancer with these compounds.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23260109P | 2009-08-10 | 2009-08-10 | |
US61/232,601 | 2009-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011019634A2 WO2011019634A2 (en) | 2011-02-17 |
WO2011019634A3 true WO2011019634A3 (en) | 2011-06-09 |
Family
ID=43586759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/044839 WO2011019634A2 (en) | 2009-08-10 | 2010-08-09 | Aryl substituted sulfonamide compounds and their use as anticancer agents |
Country Status (3)
Country | Link |
---|---|
US (1) | US8119683B2 (en) |
TW (1) | TWI405754B (en) |
WO (1) | WO2011019634A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012064744A2 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
US9657033B2 (en) | 2012-05-08 | 2017-05-23 | Lycera Corporation | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
US9394315B2 (en) | 2012-05-08 | 2016-07-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
CN102875549B (en) * | 2012-09-14 | 2015-11-04 | 浙江大学 | 7-virtue (first) amido-5-amido-6-7-azaindole derivatives and preparation and purposes |
US9546162B2 (en) | 2013-09-27 | 2017-01-17 | Allergan, Inc. | Compounds and methods for skin repair |
JP6454346B2 (en) | 2013-12-20 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | Aromatic heterocyclic compounds and their application in medicine |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
CN106132422A (en) | 2014-02-27 | 2016-11-16 | 莱斯拉公司 | Use the adoptive cellular therapy & related methods for the treatment of of the agonist of retinoic acid receptors related orphan receptor y |
JP6726658B2 (en) * | 2014-04-11 | 2020-07-22 | イェン、ユンYEN,Yun | Histone deacetylase inhibitor |
AU2015256190B2 (en) | 2014-05-05 | 2019-08-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
JP2018510135A (en) | 2015-02-11 | 2018-04-12 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Substituted pyrazole compounds as RORγT inhibitors and uses thereof |
CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
KR20180025894A (en) | 2015-06-11 | 2018-03-09 | 라이세라 코퍼레이션 | Benzo [B] [1,4] oxazinesulfonamides and related compounds for use as agonists of RORY and the treatment of diseases |
WO2017075178A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
EP3368539B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as ror gamma t inhibitors and uses thereof |
WO2018165501A1 (en) * | 2017-03-10 | 2018-09-13 | Lycera Corporation | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATMENT OF DISEASE |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080020566A (en) * | 2006-08-31 | 2008-03-05 | 타이페이 메디컬 유니이버시티 | Indoline-sulfonamides compounds |
WO2009070645A1 (en) * | 2007-11-29 | 2009-06-04 | The Ohio University Research Foundation | Indoles, derivatives, and analogs thereof and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200301251A (en) * | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
-
2010
- 2010-08-09 WO PCT/US2010/044839 patent/WO2011019634A2/en active Application Filing
- 2010-08-09 US US12/852,755 patent/US8119683B2/en active Active
- 2010-08-10 TW TW099126681A patent/TWI405754B/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080020566A (en) * | 2006-08-31 | 2008-03-05 | 타이페이 메디컬 유니이버시티 | Indoline-sulfonamides compounds |
WO2009070645A1 (en) * | 2007-11-29 | 2009-06-04 | The Ohio University Research Foundation | Indoles, derivatives, and analogs thereof and uses thereof |
Non-Patent Citations (4)
Also Published As
Publication number | Publication date |
---|---|
US20110039880A1 (en) | 2011-02-17 |
WO2011019634A2 (en) | 2011-02-17 |
TW201124379A (en) | 2011-07-16 |
US8119683B2 (en) | 2012-02-21 |
TWI405754B (en) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011019634A3 (en) | Aryl substituted sulfonamide compounds and their use as anticancer agents | |
TN2012000401A1 (en) | Heterocyclic compound | |
WO2012139039A3 (en) | Bisphenol compounds and methods for their use | |
HRP20150692T8 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
EA201200102A1 (en) | COMPOUNDS APPLICABLE AS A MEDICINE | |
MY166026A (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
GEP20156310B (en) | Methods of using c-met modulators | |
JO3131B1 (en) | Chemical Compounds | |
WO2011123946A8 (en) | Kinase inhibitors and method of treating cancer with same | |
MX2013011329A (en) | Combinations of akt inhibitor compounds and erlotinib, and methods of use. | |
EP2542081A4 (en) | Compounds for treatment of cancer | |
SG190819A1 (en) | Nampt and rock inhibitors | |
PL2959900T4 (en) | Compound for treatment of cancer | |
MY159850A (en) | Tetracyclic compounds | |
WO2011119777A3 (en) | Compositions and methods for treatment of neurodegenerative disease | |
EP2331520A4 (en) | Rosamine derivatives as agents for the treatment of cancer | |
HK1193823A1 (en) | Chromenone compounds as pi 3 -kinase inhibitors for the treatment of cancer pi3- | |
WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
MX351863B (en) | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof. | |
WO2012061754A3 (en) | Compounds and methods for treating autoimmune diseases | |
EP2608671A4 (en) | Compounds for treatment of cancer | |
TN2012000469A1 (en) | Use of novel pan-cdk inhibitors for treating tumors | |
WO2012074869A8 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
EA201590656A1 (en) | AZAINDOLINS | |
MX2013005825A (en) | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10808575 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10808575 Country of ref document: EP Kind code of ref document: A2 |